Search for: "Par Pharmaceutical Inc. "
Results 61 - 80
of 171
Sort by Relevance
|
Sort by Date
30 Jun 2014, 10:28 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited; Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE; Caraco Pharmaceutical… [read post]
11 Jun 2014, 6:30 am
©2014 Amaxx Risk Solutions, Inc. [read post]
9 Jun 2014, 11:14 am
” “[P]urposes not prohibited by this chapter” is defined as“[a]ny peaceful purpose related to an industrial, agricultural, research, medical, or pharmaceutical activity or other activity,” and other specific purposes. [read post]
20 Mar 2014, 5:34 pm
Barr’s ANDA filing was second to that of Par Pharmaceuticals, Inc. [read post]
17 Mar 2014, 11:03 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited (these three companies are, collectively, "Mylan"); Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun… [read post]
27 Jan 2014, 9:47 am
("Par Pharmaceutical Companies") and Par Pharmaceutical, Inc. [read post]
10 Oct 2013, 8:42 am
Par Pharmaceutical Companies Inc. ($45 million) Par Pharmaceutical Companies, Inc., one of the top five U.S. generic pharmaceutical companies, pleaded guilty to federal criminal charges and agreed to settle civil allegations involving the company’s promotion of the drug Megace ES. [read post]
1 Oct 2013, 11:41 am
Despite a showdown in Congress about health care reform’s future that threatens to bring funding of the U.S. government to a halt and a host of recent security and other concerns about the security and operational readiness of its enrollment platform and details of the implementation of the marketplaces in many states that will provide the offered coverage, the Obama Administration is touting today, October 1, 2013, as the first day that Americans can apply for enrollment in coverage offered… [read post]
30 Sep 2013, 8:12 am
District Court for the District of Delaware against Apotex Corp.; Hetero USA Inc.; Lupin Ltd.; Mylan Pharmaceuticals, Inc.; Par Pharmaceuticals, Inc.; Ranbaxy Laboratories Ltd.; and related companies and subsidiaries. [read post]
13 Sep 2013, 7:43 am
Coming in "third place" was Par Pharmaceuticals based in Woodcliff Lake, New Jersey. [read post]
6 Aug 2013, 6:03 pm
Report Highlights Concerns About Security Of Sensitive Personal Information Americans Will Share With HHS Exchange Portal AS HHS Invites Consumers To Set Up Personal Accounts The reported finding that the Department of Health & Human Services (HHS) has yet to complete the necessary security arrangements and testing for the web-portal Incomplete security arrangements and testing necessary to ensure the security of personal health and other information shared by consumers on the health… [read post]
30 Jul 2013, 2:01 pm
Lexis 1688, at *36) to Merrell Dow Pharmaceuticals, Inc. v. [read post]
29 Jul 2013, 4:00 am
Le Blogue du CRLUne substitution de sûreté peut être obtenue par ordonnance de sauvegardeDans Sarailis c. [read post]
25 Jun 2013, 9:51 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
25 Jun 2013, 6:52 am
Soon after, two other companies, Actavis and Paddock (the latter in agreement with a third company, Par Pharmaceutical) had filed Abbreviated New Drug Applications for generic drugs modeled after AndroGel, declaring that Solvay’s patent 6,503,894 was invalid, under paragraph 4 of the Hatch-Waxman Act. [read post]
24 Jun 2013, 10:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
24 Jun 2013, 6:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
23 Jun 2013, 8:50 pm
• Defendants: Par Pharmaceutical Inc.; Actavis Elizabeth LLC; Actavis Inc. [read post]
21 May 2013, 2:26 pm
Earlier this month, the Department of Justice announced a $500 million settlement it reached with Ranbaxy USA Inc., a subsidiary of the Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited. [read post]
11 Apr 2013, 4:57 am
FTC Sues Regarding AndroGel Patent SettlementThe Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of more than… [read post]